Pal Pacher
Cited by
Cited by
Nitric oxide and peroxynitrite in health and disease
P Pacher, JS Beckman, L Liaudet
Physiological reviews 87 (1), 315-424, 2007
The endocannabinoid system as an emerging target of pharmacotherapy
P Pacher, S Bátkai, G Kunos
Pharmacological reviews 58 (3), 389-462, 2006
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol
PAL Pacher, A Nivorozhkin, C Szabó
Pharmacological reviews 58 (1), 87-114, 2006
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
G Haskó, J Linden, B Cronstein, P Pacher
Nature reviews Drug discovery 7 (9), 759-770, 2008
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
D Osei-Hyiaman, M DePetrillo, P Pacher, J Liu, S Radaeva, S Bátkai, ...
The Journal of clinical investigation 115 (5), 1298-1305, 2005
CD39 and CD73 in immunity and inflammation
L Antonioli, P Pacher, ES Vizi, G Haskó
Trends in molecular medicine 19 (6), 355-367, 2013
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
OV Evgenov, P Pacher, PM Schmidt, G Haskó, HHHW Schmidt, JP Stasch
Nature reviews Drug discovery 5 (9), 755-768, 2006
Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats
P Pacher, T Nagayama, P Mukhopadhyay, S Bátkai, DA Kass
Nature protocols 3 (9), 1422-1434, 2008
Activation of the peripheral endocannabinoid system in human obesity
S Engeli, J Bohnke, M Feldpausch, K Gorzelniak, J Janke, S Bátkai, ...
Diabetes 54 (10), 2838-2843, 2005
Immunity, inflammation and cancer: a leading role for adenosine
L Antonioli, C Blandizzi, P Pacher, G Haskó
Nature Reviews Cancer 13 (12), 842-857, 2013
Endocannabinoid signaling at the periphery: 50 years after THC
M Maccarrone, I Bab, T Bíró, GA Cabral, SK Dey, V Di Marzo, JC Konje, ...
Trends in pharmacological sciences 36 (5), 277-296, 2015
Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?
P Pacher, V Kecskemeti
Current pharmaceutical design 10 (20), 2463-2475, 2004
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
N Agarwal, P Pacher, I Tegeder, F Amaya, CE Constantin, GJ Brenner, ...
Nature neuroscience 10 (7), 870-879, 2007
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease
JP Stasch, P Pacher, OV Evgenov
Circulation 123 (20), 2263-2273, 2011
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity
M Bluher, S Engeli, N Kloting, J Berndt, M Fasshauer, S Bátkai, P Pacher, ...
Diabetes 55 (11), 3053-3060, 2006
Evidence for novel cannabinoid receptors
M Begg, P Pacher, S Bátkai, D Osei-Hyiaman, L Offertáler, FM Mo, J Liu, ...
Pharmacology & therapeutics 106 (2), 133-145, 2005
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
P Pacher, R Mechoulam
Progress in lipid research 50 (2), 193-211, 2011
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
M Rajesh, P Mukhopadhyay, S Bátkai, V Patel, K Saito, S Matsumoto, ...
Journal of the American College of Cardiology 56 (25), 2115-2125, 2010
Drug-induced mitochondrial dysfunction and cardiotoxicity
ZV Varga, P Ferdinandy, L Liaudet, P Pacher
American Journal of Physiology-Heart and Circulatory Physiology 309 (9 …, 2015
Resveratrol induces mitochondrial biogenesis in endothelial cells
A Csiszar, N Labinskyy, JT Pinto, P Ballabh, H Zhang, G Losonczy, ...
American Journal of Physiology-Heart and Circulatory Physiology 297 (1), H13-H20, 2009
The system can't perform the operation now. Try again later.
Articles 1–20